Multiple Myeloma Market to Witness Growth During the Forecast Period (2022-32), Estimates DelveInsight | Key Companies – AstraZeneca, Bayer, Acetilion, Tenax Therapeutics, Amgen

Las Vegas, Nevada, United States, DelveInsight’s “Multiple Myeloma Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the Multiple Myeloma, historical and forecasted epidemiology as well as the Multiple Myeloma market trends in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.

Multiple Myeloma Overview

Multiple myeloma is a cancer of plasma cells. In general, when plasma cells become cancerous and grow out of control, this is called multiple myeloma. The plasma cells make an abnormal protein (antibody) known by several different names, including monoclonal immunoglobulin, monoclonal protein (M-protein), M-spike, or paraprotein. Normal plasma cells are found in the bone marrow and are a significant part of the immune system.

Multiple Myeloma Epidemiological Insights

●The Overall risk of progression based on a small cohort study was found to be 10% per year for the first 5 years, 3% per year in the next 5 years, and 1% per year afterward; the cumulative probability of progression was 73% after 15 years.
●Multiple Myeloma accounts for 1% of all cancers and is the 2nd most common hematologic malignancy after lymphoma with an estimated 24,2802 to 30,330 new cases and 12,650 deaths.
●Multiple Myeloma is extremely rare in those less than 30 years of age with a reported frequency of 0.02% to 0.3% and appears to occur slightly more frequently in men.

Multiple Myeloma Treatment Market

The treatment involved is as follows
●Targeted therapy – Targeted drug treatments focus on specific weaknesses present within cancer cells. By blocking these abnormalities, targeted drug treatments can cause cancer cells to die.
●Immunotherapy – Immunotherapy uses your immune system to fight cancer. Your body’s disease-fighting immune system may not attack your cancer because the cancer cells produce proteins that help them hide from the immune system cells. Immunotherapy works by interfering with that process.
●Chemotherapy – Chemotherapy uses drugs to kill cancer cells. The drugs kill fast-growing cells, including myeloma cells. High doses of chemotherapy drugs are used before a bone marrow transplant.

Leading Companies Working in the Multiple Myeloma Market
●GlaxoSmithKline
●Bristol-Myers Squibb/Bluebird bio
●Oncopeptides AB
●Secura Bio
●Amgen
●Takeda Pharmaceutical
And many others

Promising Therapies in the Multiple Myeloma Pipeline
●Venetoclax
●TNB-383B
●Vasopressin
●Vilaprisan
●Ophtamesone
●Fulacimstat
And many others

Learn more about the key companies and emerging therapies @ Multiple Myeloma Therapeutics Market Analysis

Scope of the Multiple Myeloma Market Report
Study Period: 2019–2032
Coverage: 7MM [The United States, EU4 (Germany, France, Italy, Spain), the United Kingdom, Japan]
Key Multiple Myeloma Companies: GlaxoSmithKline, Bristol-Myers Squibb, Oncopeptides AB, Secura Bio, Amgen, Takeda Pharmaceutical, and many others
Key Multiple Myeloma Pipeline Therapies: Venetoclax, TNB-383B, Vasopressin, Vilaprisan, Ophtamesone, Fulacimstat, and many others.
Therapeutic Assessment: Multiple Myeloma current marketed and emerging therapies
Multiple Myeloma Market Dynamics: Multiple Myeloma market drivers and barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
Unmet Needs, KOL’s views, Analyst’s views, Multiple Myeloma Market Access and Reimbursement

Table of Contents
1. Multiple Myeloma Market Key Insights
2. Multiple Myeloma Market Report Introduction
3. Multiple Myeloma Market Overview at a Glance
4. Multiple Myeloma Market Executive Summary
5.Disease Background and Overview
6. Multiple Myeloma Treatment and Management
7. Multiple Myeloma Epidemiology and Patient Population
8. Patient Journey
9. Multiple Myeloma Emerging Drugs
10.7MM Multiple Myeloma Market Analysis
11. Multiple Myeloma Market Outlook
12. Potential of Current and Emerging Therapies
13. KOL Views
14. Multiple Myeloma Market Drivers
15. Multiple Myeloma Market Barriers
16. Unmet Needs
17. SWOT Analysis
18. Appendix
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

Download the sample pages @ Multiple Myeloma Market Outlook

Trending Reports
Genital Warts Market

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Contact Us
Adya Kaul
info@delveinsight.com
www.delveinsight.com